FairValu
BETA
DANAHER CORP /DE/

DANAHER CORP /DE/

DHR

Diagnostics & Research • Healthcare

Current Price
$172.000.00%
Market Cap
$121.74B
Volume
-
Avg Vol (3M): -
Next Earnings
-
52 Week Range
Low: $--High: $--

Comprehensive AI Analysis

AI Analysis of DHR's Strategic Position

Access detailed SWOT, moat analysis, growth sustainability, and risk assessment powered by Vertex AI.

Summary

Multi-agent institutional research for DHR

Factor Scorecard

Factor scores will populate once the financial statement data finishes loading.

Price Chart

DHR via TradingView

Loading TradingView chart...

Overview

Quarterly income statement data isn't available from current approved sources.

No Data

No annual financial data available.

Analyst Consensus

0 Analysts
Recommendation mix unavailable from the current feed
Buy
-
Hold
-
Sell
-

Coverage count comes from 0 analyst opinions, but the Buy/Hold/Sell mix was not included in the current payload.

Price Target

N/AAverage Target
Low
N/A
Current
$172.00
High
N/A

Peer Comparison

TickerPrice
DHRDANAHER CORP /DE/
$172.00
Financial data not available for quantitative analysis.
Company News & Profile

Loading latest news...

About the Company

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Next Earnings Date

Jul 21, 2026